Genzyme Bets Big on Biosurgery
Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.